Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia

Leukemia Research

Volumn 23, Issue 12, 1999, Pages 1121-1126

  Schirmer, Michael ^a   Geisen, Francoise ^a   Tiefenthaler, Martin ^a   Konwalinka, Günther ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Bone marrow progenitors; Chronic myelogenous leukemia; Cladribine; Gemcitabine; Graft purging; Nucleoside analogs

Indexed keywords

CLADRIBINE; DEOXYCYTIDINE KINASE; GEMCITABINE; NUCLEOSIDE ANALOG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; ERYTHROID PRECURSOR CELL; GRANULOCYTE PRECURSOR; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW CELLS; BONE MARROW PURGING; CELLS, CULTURED; CLADRIBINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; TUMOR STEM CELLS;

EID: 0032699986     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00142-3     Document Type: Article

References (19)

1. Bhatia R., Forman S.J. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol. Oncol. Clin. North. Am. 12:1998;151.
2. Singer I.O., Franklin I.M. Autografting as first line treatment for chronic myeloid leukaemia. J. Clin. Pathol. 51:1998;92.
3. Enright H., McGlave P. Bone marrow transplantation for chronic myelogenous leukemia. Curr. Opin. Oncol. 10:1998;100.
4. Carson D.A., Wasson D.B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 62:1983;737.
5. Petzer A.L., Bilgeri R., Zilian U., Haun M., Geisen F.H., Pragnell I., Braunsteiner H., Konwalinka G. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood. 78:1991;2583.
6. Saven A., Piro L.D., Lemon R.H., Figueroa M.L., Kosty M., Ellison D.J., Beutler E. Complete hematological remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer. 73:1994;2953.
7. Gollard R., Miller W.E., Piro L.D., Saven A. 2-Chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia. Leuk. Lymph. 28:1997;183.
8. Dann E.J., Anastasi J., Larson R.A. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J. Clin. Oncol. 16:1998;1498.
9. Santini V., Bernabei A., Gozzini A., Scappini B., Zoccolante A., D'Ippolito G., Figuccia M., Ferrini P.R. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica. 82:1997;11.
10. Grunewald R., Kantarjian H., Du M., Faucher K., Tarassoff P., Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacological study. J. Clin. Oncol. 10:1992;406.
11. Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin. Hematol. 31:1991;40.
12. Plunkett W., Gandhi V., Chubb S., Nowak B., Heinamann V., Mineiski S., Sen A., Hertel L.W., Grindey G.B. 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides. Nucleotides. 8:1989;775.
13. Bilgeri R., Petzer A.L., Zilian U., Geisen F.H., Schirmer M., Haun M., Konwalinka G. Effect of deoxycytidine on 2-chlorodeoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells. Exp. Hematol. 21:1993;432.
14. Orr R.M., Talbot D.C., Aherne G.W., Fisher T.C., Serafinowski P., Harrap K.R. 2′-deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′-deoxyadenosine resistance in lymphoid cell lines. Clin. Cancer Res. 1:1995;391.
15. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., Vermorken J.B., Pinedo H.M., Peters G.J. Development and characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54:1994;4138.
16. Schirmer M., Stegmann A.P.A., Geisen F., Konwalinka G. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Exp. Hem. 26:1998;1223.
17. Böyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens. 4:1974;269.
18. Coulombel L., Eaves A.C., Eaves C.J. Enzymatic treatment of long-term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. Blood. 62:1983;291.
19. Carlo-Stella C., Mangoni L., Almici C., Caramatti C., Cottafavi L., Dotti G.P., Rizzoli V. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow. Transplant. 14:1994;425.